Concerns about injectable naltrexone for opioid dependence

Affiliations

Comment

Daniel Wolfe et al. Lancet. 2011.

. 2011 Apr 30;377(9776):1468-70.

doi: 10.1016/S0140-6736(10)62056-9.

¹ Open Society Institute, International Harm Reduction Development Program, New York, NY 10019, USA. dwolfe@sorosny.org

No abstract available

Comment in

Injectable extended-release naltrexone for opioid dependence.
Woody GE, Metzger DS. Woody GE, et al. Lancet. 2011 Aug 20;378(9792):664-5; author reply 666. doi: 10.1016/S0140-6736(11)61330-5. Lancet. 2011. PMID: 21856476 No abstract available.
Injectable extended-release naltrexone for opioid dependence.
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Krupitsky E, et al. Lancet. 2011 Aug 20;378(9792):665; author reply 666. doi: 10.1016/S0140-6736(11)61331-7. Lancet. 2011. PMID: 21856477 No abstract available.
Injectable extended-release naltrexone for opioid dependence.
Throckmorton DC, Temple R, Rappaport BA, Roca R, Winchell CJ. Throckmorton DC, et al. Lancet. 2011 Aug 20;378(9792):665-6; author reply 666. doi: 10.1016/S0140-6736(11)61332-9. Lancet. 2011. PMID: 21856478 No abstract available.

Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Krupitsky E, et al. Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9. Lancet. 2011. PMID: 21529928 Clinical Trial.